Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with Exemestane and Everolimus in HR+ Metastatic Breast Cancer
NCT01627067Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2012
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Progression-Free Survival up to 67 months and Compare Progression Free Survival Between Obese and Overweight Participants up to 67 months. Started Sep 2012; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01627067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627067.